The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Regeneron Pharmaceuticals Inc.’s current liabilities increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019.
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
Regeneron Pharmaceuticals Inc.’s noncurrent liabilities decreased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019.
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Regeneron Pharmaceuticals Inc.’s total liabilities increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019.
Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Regeneron Pharmaceuticals Inc.’s stockholders’ equity increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019.